Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Annual account missing NBB
Fiscal year 2025 was expected before 31 October 2025 and has not been filed.
Financials
Financial year 2024
Pharmadil from Dilbeek, company number BE0549774521, closed financial year 2024 with a result of € -69,128 after tax. For that financial year Pharmadil recorded a gross margin of € 159,629 and equity of € -88,047. Compared with financial year 2023, the result moved from € -43,197 to € -69,128. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on November 13, 2024.
€ -88,047
▼ € 69,128 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -69,128
▼ 60 % more loss than in 2023
Profit after tax over the fiscal year.
€ 63,617
▲ 211% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -113,047.
People and assets in 2024
2
Average over the fiscal year, from the social balance sheet.
€ 137,078
▲ 3% vs 2023
€ 68,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 349,988
▼ 22% vs 2023
€ 59,842 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 112,444
▲ 31% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 22,521
▲ 40% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|
| Gross margin | € 211,961 | € 181,696 | € 159,629 | ▼ 12% |
| Profit after taxes | € 4,116 | € -43,197 | € -69,128 | ▼ € 25,931 |
| Equity | € 24,278 | € -18,919 | € -88,047 | ▼ € 69,128 |
| Total debts | € 776,358 | € 749,150 | € 708,698 | ▼ 5% |
| Cash | € 24,190 | € 20,484 | € 63,617 | ▲ 211% |
| Retained profit | € -722 | € -43,919 | € -113,047 | ▼ € 69,128 |
| Bank debt | € 544,089 | € 450,756 | € 349,988 | ▼ 22% |
| Balance sheet total | € 800,636 | € 730,231 | € 620,651 | ▼ 15% |
| Employees (FTE) | 2 | 2 | 2 |
Key figures of Pharmadil, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 October 2025.
What happened to Pharmadil?
What happened at Pharmadil in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 69,128. filed late Source: NBB ↗
- Msp Invest BV became a director. NBB
- New establishment in Dilbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 4,116 profit in 2022 to € 69,128 loss in 2024.
Best year ever: 2022, with € 4,116 profit.
On average € 79,800 of value added per employee in 2024.
A new publication or filing at Pharmadil? We notify you, reason included.
Follow PharmadilDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of MSP INVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PharmadilBehind Pharmadil is Msp Invest BV. The shares are held by MSP INVEST (99.9%).
Directors
According to the 2024 annual accounts
since 2019
Shareholders
99.9%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Baron R. de Vironlaan 162
1700 Dilbeek
Ninoofsesteenweg 70
1700 Dilbeek
Active since 1 April 2014
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Website info
Features
Security
Network
Details
- Company number
- 0549.774.521
- VAT number
- BE 0549.774.521
- Registered office
- Baron R. de Vironlaan 162, 1700 Dilbeek
- Names & denominations
- Pharmadil
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 March 2014
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- apotheekdilbeek.be
- Activities · NACE
Detailhandel in farmaceutische producten